Crinetics Pharmaceuticals, Inc. announced on June 30, 2025, that it would present eight abstracts from its clinical development programs at the Endocrine Society’s Annual Meeting, ENDO 2025, held from July 12-15, 2025.
Four abstracts will report results from the PALSONIFY (paltusotine) development program, including open-label extension data from the Phase 3 PATHFNDR trials, highlighting long-term efficacy, safety, and symptom control in acromegaly patients. These presentations will show PALSONIFY's consistent biochemical and symptomatic disease control.
Additionally, three abstracts from the atumelnant clinical development program will be presented, featuring Phase 2 trial results in congenital adrenal hyperplasia (CAH), including reductions in adrenal volume and 11-oxygenated androgens. New data from the early-stage program CRN12755 for Graves’ hyperthyroidism and orbitopathy will also be showcased, demonstrating the breadth of Crinetics' pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.